Biotech

All Articles

AstraZeneca posts data on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed an early examine the performance of its internal antibody-drug c...

iTeos- GSK's TIGIT star reveals relevant renovation

.After declaring a period 3 launch based on favorable midstage end results, iTeos and also GSK are l...

More collective FDA can easily accelerate rare illness R&ampD: report

.The FDA needs to be extra open and also joint to release a surge in commendations of uncommon ailme...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an uncommonly hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bic...

Atea's COVID antiviral falls short to stop hospital stays in period 3

.Atea Pharmaceuticals' antiviral has failed one more COVID-19 test, yet the biotech still keeps out ...

Neurocrine's proposal to spare schizophrenia prospect stops working

.Neurocrine Biosciences' mental illness program pivot has actually stopped working. The biotech was ...

Sanofi pays $110M upfront for late-stage radioligand therapy

.Sanofi has actually created an overdue access to the radioligand event, paying for one hundred mill...

F 2G rears $100M for second try to acquire brand-new antifungal to market

.After F2G's 1st effort to obtain a new course of antifungal to market was thwarted by the FDA, the ...

Moderna targets $1.1 B in R&ampD spending cuts, drops 5 courses surrounded by profits tensions

.Moderna has vowed to cut R&ampD costs through $1.1 billion through 2027. The choice to shrink the b...

Sanofi's $80M bet on Key dystrophy medication ends in stage 3 lose big

.Simply 4 months after Sanofi wager $80 million in ahead of time money on Key Rehabs' losmapimod, th...